 GAITHERSBURG, Md., July 29, 2021 GLOBE NEWSWIRE -- Emergent BioSolutions Inc. NYSE:EBS announced today that the U.S. Food and Drug Administration FDA is allowing Emergents Bayview manufacturing facility to resume production of Johnson Johnsons JJ Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with JJ and FDA to execute on Emergents quality enhancement plan. 